Table 1 Baseline characteristics of the analyzed cohort within the GMMG-MM5 trial.

From: Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Variablea

Subcategory

Value n (%)b

Age

years [median (range)]

59 (32–70)

Gender

male

284 (59.2)

female

196 (40.8)

Study arm

A1

116 (24.2)

A2

121 (25.2)

B1

114 (23.8)

B2

129 (26.9)

Immunoglobulin type

IgG kappa

208 (43.3)

IgG lambda

79 (16.5)

IgA kappa

63 (13.1)

IgA lambda

39 (8.1)

Bence Jones kappa

59 (12.3)

Bence Jones lambda

27 (5.6)

IgD lambda

5 (1.0)

R-ISS

I

128 (26.7)

II

261 (54.4)

III

65 (13.5)

missing

26 (5.4)

High-risk cytogenetics

no

206 (43.9)

yes

222 (46.3)

missing

52 (10.8)

del(17p)

no

380 (79.2)

yes

55 (11.5)

missing

45 (9.4)

t(4;14)

no

383 (79.8)

yes

48 (10.0)

missing

49 (10.2)

t(14;16)

no

411 (85.6)

yes

12 (2.5)

missing

57 (11.9)

gain(1q21)

no

260 (54.2)

yes

174 (36.3)

missing

46 (9.6)

  1. aThe analysis included 480 (79.5%) of 604 patients randomized within the GMMG-MM5 trial with an MS sample at baseline and at least one additional time point (post induction, prior to maintenance therapy/observation or after 1 year of maintenance treatment/observation).
  2. bUnless otherwise indicated.
Back to article page